{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T21:38:44Z","timestamp":1757453924487},"reference-count":37,"publisher":"Elsevier BV","issue":"52","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Israel Institute for Biological Research","award":["SB-146"],"award-info":[{"award-number":["SB-146"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.vaccine.2017.11.015","type":"journal-article","created":{"date-parts":[[2017,11,23]],"date-time":"2017-11-23T09:45:59Z","timestamp":1511430359000},"page":"7213-7216","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["An in vitro cell-based potency assay for pharmaceutical type A botulinum antitoxins"],"prefix":"10.1016","volume":"35","author":[{"given":"Amram","family":"Torgeman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eran","family":"Diamant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilach","family":"Levin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alon Ben","family":"David","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eyal","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meni","family":"Girshengorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ohad","family":"Mazor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronit","family":"Rosenfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Zichel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.11.015_b0005","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jama.285.8.1059","article-title":"Botulinum toxin as a biological weapon: medical and public health management","volume":"285","author":"Arnon","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2017.11.015_b0010","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1128\/MMBR.46.1.86-94.1982","article-title":"Bacterial toxins: a table of lethal amounts","volume":"46","author":"Gill","year":"1982","journal-title":"Microbiol Rev"},{"key":"10.1016\/j.vaccine.2017.11.015_b0015","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1124\/pr.116.012658","article-title":"Botulinum neurotoxins: biology, pharmacology, and toxicology","volume":"69","author":"Pirazzini","year":"2017","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.vaccine.2017.11.015_b0020","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrmicro3295","article-title":"Botulinum neurotoxins: genetic, structural and mechanistic insights","volume":"12","author":"Rossetto","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2017.11.015_b0025","first-page":"219","article-title":"Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins","volume":"19","author":"Atassi","year":"1999","journal-title":"Crit Rev Immunol"},{"key":"10.1016\/j.vaccine.2017.11.015_b0030","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1152\/physrev.2000.80.2.717","article-title":"Neurotoxins affecting neuroexocytosis","volume":"80","author":"Schiavo","year":"2000","journal-title":"Physiol Rev"},{"key":"10.1016\/j.vaccine.2017.11.015_b0035","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1123654","article-title":"SV2 is the protein receptor for botulinum neurotoxin A","volume":"312","author":"Dong","year":"2006","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.vaccine.2017.11.015_b0040","first-page":"299","article-title":"Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E","volume":"59","author":"Centers for Disease Control and Prevention (CDC)","year":"2010","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2017.11.015_b0045","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/DMP.0b013e318158c5fd","article-title":"Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities","volume":"1","author":"Dembek","year":"2007","journal-title":"Disaster Med Public Health Prep"},{"key":"10.1016\/j.vaccine.2017.11.015_b0050","unstructured":"In brief: heptavalent botulism antitoxin. The Medical Letter On Drugs and Therapeutics. 2014\/05\/30 ed2014. p. 44."},{"key":"10.1016\/j.vaccine.2017.11.015_b0055","unstructured":"European Directorate for the Quality of Medicines and Healthcare. Botulinum antitoxin. In: European Pharmacopoeia, 8th ed.; EDQM Council of Europe: Strasbourg, France; 2014. p. 1029."},{"key":"10.1016\/j.vaccine.2017.11.015_b0060","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000052139","article-title":"Botulinum toxin antibody testing: comparison between the immunoprecipitation assay and the mouse diaphragm assay","volume":"45","author":"Dressler","year":"2001","journal-title":"Eur Neurol"},{"key":"10.1016\/j.vaccine.2017.11.015_b0065","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1212\/WNL.50.6.1624","article-title":"Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response","volume":"50","author":"Hanna","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.vaccine.2017.11.015_b0070","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1045-1056(02)00074-X","article-title":"Evaluation of a botulinum fragment C-based ELISA for measuring the humoral immune response in primates","volume":"31","author":"Lindsey","year":"2003","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2017.11.015_b0075","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1212\/WNL.50.5.1463","article-title":"A radioimmuno-precipitation assay for antibodies to botulinum A","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.vaccine.2017.11.015_b0080","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3390\/toxins8100276","article-title":"Development of an innovative in vitro potency assay for anti-botulinum antitoxins","volume":"8","author":"Rosen","year":"2016","journal-title":"Toxins"},{"key":"10.1016\/j.vaccine.2017.11.015_b0085","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/10408410701364562","article-title":"Botulism diagnostics: from clinical symptoms to in vitro assays","volume":"33","author":"Cai","year":"2007","journal-title":"Crit Rev Microbiol"},{"key":"10.1016\/j.vaccine.2017.11.015_b0090","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.1016\/j.febslet.2007.08.078","article-title":"A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies","volume":"581","author":"Pellett","year":"2007","journal-title":"FEBS Lett"},{"key":"10.1016\/j.vaccine.2017.11.015_b0095","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/1087057109354779","article-title":"Development of cell-based assays to measure botulinum neurotoxin serotype A activity using cleavage-sensitive antibodies","volume":"15","author":"Nuss","year":"2010","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.vaccine.2017.11.015_b0100","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.vascn.2010.01.003","article-title":"Comparison of the primary rat spinal cord cell (RSC) assay and the mouse bioassay for botulinum neurotoxin type A potency determination","volume":"61","author":"Pellett","year":"2010","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.vaccine.2017.11.015_b0105","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bbrc.2010.12.132","article-title":"Embryonic stem cell-derived neurons are a novel, highly sensitive tissue culture platform for botulinum research","volume":"405","author":"McNutt","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.vaccine.2017.11.015_b0110","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.bbrc.2010.11.128","article-title":"Sensitive and quantitative detection of botulinum neurotoxin in neurons derived from mouse embryonic stem cells","volume":"404","author":"Pellett","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.vaccine.2017.11.015_b0115","doi-asserted-by":"crossref","first-page":"e49516","DOI":"10.1371\/journal.pone.0049516","article-title":"Botulinum neurotoxin serotype A specific cell-based potency assay to replace the mouse bioassay","volume":"7","author":"Fernandez-Salas","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2017.11.015_b0120","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/toxsci\/kfr354","article-title":"Novel application of human neurons derived from induced pluripotent stem cells for highly sensitive botulinum neurotoxin detection","volume":"126","author":"Whitemarsh","year":"2012","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.vaccine.2017.11.015_b0125","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1586\/14737159.2014.867808","article-title":"Recent developments in cell-based assays and stem cell technologies for botulinum neurotoxin research and drug discovery","volume":"14","author":"Kiris","year":"2014","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.vaccine.2017.11.015_b0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vascn.2017.04.013","article-title":"Assessment of ELISA as endpoint in neuronal cell-based assay for BoNT detection using hiPSC derived neurons","volume":"88","author":"Pellett","year":"2017","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.vaccine.2017.11.015_b0135","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3390\/toxins9070230","article-title":"SiMa cells for a serotype specific and sensitive cell-based neutralization test for botulinum toxin A and E","volume":"9","author":"Bak","year":"2017","journal-title":"Toxins"},{"key":"10.1016\/j.vaccine.2017.11.015_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2017.09.007","article-title":"Immuno-detection of cleaved SNAP-25 from differentiated mouse embryonic stem cells provides a sensitive assay for determination of botulinum A toxin and antitoxin potency","author":"Yadirgi","year":"2017","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2017.11.015_b0145","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jim.2004.02.011","article-title":"Novel application of an in vitro technique to the detection and quantification of botulinum neurotoxin antibodies","volume":"288","author":"Hall","year":"2004","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2017.11.015_b0150","doi-asserted-by":"crossref","first-page":"9153","DOI":"10.1016\/S0021-9258(19)38824-6","article-title":"The complete sequence of botulinum neurotoxin type A and comparison with other clostridial neurotoxins","volume":"265","author":"Binz","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2017.11.015_b0155","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3390\/toxins9060180","article-title":"Role of homologous Fc fragment in the potency and efficacy of anti-botulinum antibody preparations","volume":"9","author":"Torgeman","year":"2017","journal-title":"Toxins"},{"key":"10.1016\/j.vaccine.2017.11.015_b0160","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.biologicals.2017.06.003","article-title":"Efficacy of inactivation of viral contaminants in hyperimmune horse plasma against botulinum toxin by low pH alone and combined with pepsin digestion","volume":"48","author":"Torgeman","year":"2017","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2017.11.015_b0165","first-page":"701","article-title":"Preparation and assay of the international standards for clostridium botulinum types A, B, C, D and E antitoxins","volume":"29","author":"Bowmer","year":"1963","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2017.11.015_b0170","doi-asserted-by":"crossref","first-page":"e6351","DOI":"10.1371\/journal.pone.0006351","article-title":"Isolation and chimerization of a highly neutralizing antibody conferring passive protection against lethal Bacillus anthracis infection","volume":"4","author":"Rosenfeld","year":"2009","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2017.11.015_b0175","unstructured":"Fernandez-Salas E, Wang J, Patton E, Garay L, Wong D, Kei R. Immuno-based botulinum toxin serotype A activity assays. U.S. Patent No. US 12\/403,531. (n.d.). Washington, DC: U.S. Patent and Trademark Office; 2012."},{"key":"10.1016\/j.vaccine.2017.11.015_b0180","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1006\/exnr.1997.6580","article-title":"Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies\u2013therapeutic consequences","volume":"147","author":"Goschel","year":"1997","journal-title":"Exp Neurol"},{"key":"10.1016\/j.vaccine.2017.11.015_b0185","doi-asserted-by":"crossref","first-page":"e12416","DOI":"10.1371\/journal.pone.0012416","article-title":"Characterization of botulinum neurotoxin type A neutralizing monoclonal antibodies and influence of their half-lives on therapeutic activity","volume":"5","author":"Mazuet","year":"2010","journal-title":"PloS One"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17315748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17315748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T03:34:41Z","timestamp":1659929681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17315748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":37,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0264410X17315748"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.11.015","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An in vitro cell-based potency assay for pharmaceutical type A botulinum antitoxins","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}